1.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2303, NCT00262990
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 3c-03-19, NCT00159484
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CEPO906A2401, NCT00715013
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2209, NCT00171834
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0202045, NOVARTIS-CEP0906A2207, NCI-G02-2091, NCT00041002
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2227, NCT00219297
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2213, NCT00273312
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2203, NCT00035100
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: OZM-005/CEPO906A2402, Protocol number CEP0906A2402, OZM-005, NCT00407251
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2229, NCT00411528
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE5106, P30CA043703, MSKCC-07036, CASE-IRB-5106-CC185, NCT00450866
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 03C.275, 2003-33, NCT00328458
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A1103, NCT00412789
|
|
14.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2121, NCT00420524
|
|
15.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2123, NCT00420615
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2121E1, NCT00421044
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2105, NCT00426582
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2120, NCT00448396
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 050612, CRAD001US16, 0220060307, NCT00496600
|
Mobile | Español
